Medical Device Network on MSN1d
Newronika’s DBS device gains CE Mark approval for Parkinson’s treatment
Newronika has secured CE Mark approval for its AlphaDBS device aimed at the treatment of Parkinson's disease (PD), in Europe.
Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease
Newronika, a leader in neuromodulation and adaptive deep brain stimulation (DBS) technology, announced today that it has ...
MassDevice1d
Newronika wins CE mark for adaptive DBS for Parkinson’s
Newronika announced today that it received CE mark approval for its AlphaDBS device for treating Parkinson's disease.
Hosted on MSN1mon
Newronika secures FDA’s IDE to begin adaptive deep brain stimulation system trial
Newronika has received an investigational device exemption (IDE) for its adaptive deep brain stimulation (DBS) system from the US Food and Drug Administration (FDA), allowing it to begin a pivotal ...
Yahoo Finance1mon
Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform
MILAN, Feb. 13, 2025 /PRNewswire/ -- Newronika, a global leader in advanced deep brain stimulation, is pleased to announce the successful closing of its €13.6 million Series B funding round.
WDTN1mon
Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System
MILAN, Feb. 5, 2025 /PRNewswire/ -- Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an Investigational Device Exemption ...